Sensei Biotherapeutics, Inc.

    Sensei Biotherapeutics, Inc.

    NNASDAQ:SNSE
    33.12
    USD
    -0.24
    (-0.72%)
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    -491.65
    -33.36
    -13.67
    -26.56
    -31.65
    -24.4
    -24.01
    -16.72
    -71.54
    Free Cash Flow per Basic Share
    -301.94
    -14
    -12.8
    -23.3
    -25.63
    -23.04
    -19.76
    -16.24
    -12.39
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -68.36
    -78.63
    -38.19
    95.73
    67.23
    51.85
    30.49
    14.74
    6.71
    Tangible Book Value per Share
    -68.36
    -78.63
    -38.19
    95.73
    67.23
    51.85
    30.49
    14.74
    6.71
    Basic Weighted Avg Shares
    - -
    1
    1
    1
    2
    1
    1
    1
    3
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    1
    1
    1
    1
    - -
    - -
    Net Income, GAAP
    -13
    -17
    -20
    -37
    -49
    -34
    -30
    -21
    -196
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Working Capital
    -1
    -21
    15
    144
    100
    62
    36
    17
    179
    LT Debt
    4
    - -
    1
    2
    6
    4
    2
    - -
    - -
    Total Equity
    -53
    -69
    -56
    147
    103
    65
    38
    19
    173
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    -38.88
    -40.52
    -58.4
    -74.01
    -195.26

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'26
    Jun'26
    ST Debt
    1
    1
    1
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    1
    1
    26
    Market Capitalization
    13
    42
    644

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'26
    Jun'26
    Total Current Assets
    22
    204
    189
    Cash, Cash Equivalents & STI
    21
    203
    186
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    4
    14
    10
    Payables & Accruals
    1
    9
    7
    ST Debt
    1
    1
    1
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -103.73%
    -51.57%
    Free Cash Flow
    - -
    6.79%
    -17.52%
    Net Income, GAAP
    - -
    8.73%
    -30.08%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -6.38
    -5.69
    -5.77
    - -
    -24.01
    2025
    -5.45
    -3.91
    -3.62
    - -
    -16.72
    2026
    -131.45
    -2.84
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

    • businesswire.com

      Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • gurufocus.com

      Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • gurufocus.com

      Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    • businesswire.com

      Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    • businesswire.com

      Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

    • businesswire.com

      Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    • businesswire.com

      Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

    • defenseworld.net

      Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday

    • globenewswire.com

      The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    • businesswire.com

      Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • defenseworld.net

      Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 1,973.5% in February

    • businesswire.com

      Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    • feeds.benzinga.com

      Sensei Biotherapeutics Stock Soars 230% After Faeth Deal

    • businesswire.com

      Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    • defenseworld.net

      Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis

    • globenewswire.com

      Egle Therapeutics Appoints John Celebi as Chief Executive Officer

    • feeds.benzinga.com

      What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?

    • globenewswire.com

      Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

    • globenewswire.com

      Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value